Thrilled to see Eli Lilly and Company expanding their existing license of the #AlivaMabMouse platform. @LillyPad
Full release here: https://t.co/MNmMkq3B4Q
Interested in the learning about the selection of antibody discovery platform? View this on-demand webinar here: https://t.co/JkYz86XHmZ #AntibodyDiscovery#AlivaMabDiscoveryServices
Happy to announce this Licensing Agreement with Allogene Therapeutics (@AllogeneTx) as they work towards the advancement of CAR T therapies for cancer: https://t.co/gTnIkmAOmw
Looking for a current list of all #FDAOncology drug approvals in #hematology & #oncology? Here you go: https://t.co/z2WbfnNx42. In chronological order & each concise listing contains a link to more info, including press release, package insert, etc. #MedEd
Merck, Amgen back a $30M play for Ribometrix — one of the upstarts making its mark in drugging RNA: The idea that you can drug RNA has attracted a variety of biotech startups interested in pioneering a new technology. And one of those biotechs looking to… https://t.co/Vd7NngEVr8
Happy to announce this progress in our Intellectual Property on #AlivaMabMouse and Immunoglobulin Locus Engineering. Read more here: https://t.co/wv99LXBDvp
Excited to have delivered a webinar with the team at Nature on considerations for choosing an #AntibodyDiscovery platform and the long-term, strategic implications. You can view the webinar on demand at https://t.co/5xdW73AIQt
Biotech's big-bucks buybacks begin to burn: If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's. https://t.co/Te0ys4d4zY
Have you been told you have a variant of uncertain significance in a gene on #genetictesting? It might be worth checking periodically w/ the company to see if it’s been reclassified. cc @FacingOurRisk https://t.co/ObdXzC1Ggc